libvatrep oral (SAF312) / Bausch Health 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   15 News 
  • ||||||||||  libvatrep oral (SAF312) / Novartis
    Journal:  Ocular Pharmacology and Toxicology of TRPV1 Antagonist SAF312 (Libvatrep). (Pubmed Central) -  Sep 8, 2023   
    SAF312 is a potent, selective, and noncompetitive antagonist of hTRPV1 with an acceptable preclinical safety profile for use in future clinical trials. SAF312, which was safe and well tolerated without causing delay in wound healing after PRK in rabbits, may be a potential therapeutic agent for ocular surface pain.
  • ||||||||||  Korsuva IV (difelikefalin IV) / Cara Therap, Maruishi Pharma, libvatrep oral (SAF312) / Novartis, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
    Journal:  Ocular surface itch and pain: key differences and similarities between the two sensations. (Pubmed Central) -  Aug 31, 2023   
    Identifying contributors to abnormal ocular sensations is vital for precise medical care. Novel therapeutics for these conditions aim to improve patient outcomes and quality of life.